Metabolic dysfunction-associated steatotic liver disease (MASLD) is often asymptomatic in its earlier stages, with patients who may present with a different range of phenotypes. This can pose a significant challenge for early diagnosis and appropriate management, particularly in primary care.
Professors Aleksander Krag (hepatologist from the University of Southern Denmark, Odense University Hospital) and Juan Mendive (primary care physician from the Catalan Institute of Health, University of Barcelona) examine some of these atypical forms of MASLD, such as patients with rapid disease progression or lean MASLD. In particular, they explore the modifiable drivers and optimal management in patients with rapid progression, and highlight how distribution of body fat can affect MASLD development in patients with a low BMI.
MASLD: Expecting the unexpected in primary care
Learning Objectives
To raise awareness of atypical forms of MASLD and MASH to support early identification of such patients
To improve understanding of risk factors and comorbidities for MASLD/MASH
To discuss optimal management of patients with atypical forms of MASLD/MASH, from diagnosis to treatment
The following speakers have received an honorarium from Novo Nordisk for their input to and facilitation of this educational material:
- Prof. Aleksander Krag, University of Southern Denmark, Odense University Hospital
- Prof. Juan Mendive, Catalan Institute of Health, University of Barcelona
References
1. Abe RM, et al. Cureus. 2021;13:e16855
2. Sookoian S, Pirola CJ. Aliment Pharmacol Ther. 2017;46:85–95
3. Rinella ME, et al. Hepatology. 2023;77:1797–1835
4. EASL, EASD, EASO. J Hepatol. 2024; doi: 10.1016/j.jhep.2024.04.031
5. Cusi K, et al. Endocr Pract. 2022;28:528–562
6. Kawanaka M, et al. Intern Med. 2021;60:1397–1401
